Market Intelligence, Clinical Progress, and High-Purity Reagents for Pulmonary Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MUC5B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MUC5B Recombinant Functional Domain (N-terminal D-domains / C-terminal) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View MUC5B Products |
| Gene Delivery | MUC5B Promise-ORF / Lentivirus Full-length or domain-specific ORF for stable cell line construction and cellular assays. |
View MUC5B Products |
| Benchmark Ab | Anti-MUC5B Recombinant Antibody Recombinant positive control for binding and specificity assays. |
View MUC5B Products |
| Validator | MUC5B siRNA Set For knockdown verification in functional validation assays. |
View MUC5B Products |
| Related Target A | MUC5AC Critical homolog for specificity counter-screening to prevent off-target pulmonary side effects. |
View MUC5AC Products |
| Related Target B | TGFB1 Primary upstream driver of pulmonary fibrosis and pathologic MUC5B hypersecretion. |
View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Massive molecular weight and complex native glycosylation | HEK293-expressed recombinant functional domains with native-like human post-translational modifications. |
| High homology and cross-reactivity with MUC5AC | Homolog screening panel featuring sequence-verified MUC5B and MUC5AC proteins for selectivity profiling. |
| Lack of controls | Sequence-derived recombinant benchmark antibodies included as positive controls. |
| Target knockdown validation in cell models | Sequence-verified siRNA sets designed for robust target gene silencing verification. |
Live MUC5B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MUC5B therapeutics is intensifying, with major players shifting focus from traditional non-specific mucolytics to targeted genetic medicines and highly selective monoclonal antibodies. As first-generation therapies for respiratory diseases reach the clinic, the next wave of R&D is targeting the genetic drivers of idiopathic pulmonary fibrosis (IPF)—specifically the MUC5B promoter polymorphism rs35705950—and exploiting MUC5B overexpression in mucinous adenocarcinomas.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO / siRNA | Ionis Pharmaceuticals, Alnylam | Idiopathic Pulmonary Fibrosis (IPF) | Knockdown Validation (Need sequence-verified siRNA and stable cell lines via Lentivirus) |
| Monoclonal Antibody | Academic Institutes, Biopharma | Mucinous Cancers (Lung, Gastric) | Specificity Screening (Need high-purity MUC5B vs. MUC5AC recombinant proteins) |
| Small Molecule | Boehringer Ingelheim, Roche | COPD, Chronic Bronchitis | High-Throughput Assays (Need HEK293-expressed functional domains for binding screens) |